Table 1 Pathological and clinical characteristics of patients in relation to metastasis free survival (MFS) in the screening and validation sets
Screening set (n = 31) | Validation set (n = 153) | |||||
|---|---|---|---|---|---|---|
Characteristic | Number of patients | Number of events (%) | MFS p-valuea | Number of patients | Number of events (%) | MFS p-valuea |
Age | 0.6228 | 0.0184 | ||||
≤65 years | 17 | 3 (18) | 67 | 33 (49) | ||
>65 years | 14 | 3 (21) | 86 | 27 (31) | ||
SBR histological gradeb,c | 0.0453 | 0.0008 | ||||
I + II | 11 | 0 (0) | 96 | 31 (32) | ||
III | 19 | 6 (32) | 54 | 27 (50) | ||
Lymph node statusc | 0.6825 | 0.6493 | ||||
Negative | 9 | 2 (22) | 33 | 11 (33) | ||
Positive | 21 | 3 (14) | 112 | 47 (42) | ||
Lymph node status | 0.3521 | 0.0005 | ||||
0 | 9 | 2 (22) | 33 | 11 (33) | ||
[1–3] | 18 | 2 (11) | 83 | 27 (33) | ||
>3 | 3 | 1 (33) | 29 | 20 (69) | ||
Macroscopic tumor sizec | 0.4955 | 0.0267 | ||||
≤25 mm | 20 | 3 (15) | 61 | 18 (30) | ||
>25 mm | 11 | 3 (27) | 83 | 40 (48) | ||
Macroscopic tumor sizec | 0.9925 | 0.1375 | ||||
≤30 mm | 26 | 5 (19) | 92 | 34 (37) | ||
>30 mm | 5 | 1 (20) | 52 | 24 (46) | ||
Estrogen receptor statusc | 0.2867 | 0.0005 | ||||
Negative | 10 | 1 (10) | 68 | 34 (50) | ||
Positive | 21 | 5 (24) | 85 | 26 (31) | ||
Progesterone receptor statusc | 0.2136 | 0.0005 | ||||
Negative | 11 | 1 (9) | 68 | 34 (50) | ||
Positive | 20 | 5 (25) | 85 | 26 (31) | ||
HER2 statusc | 0.8493 | 0.0595 | ||||
Negative | 22 | 5 (23) | 111 | 41 (37) | ||
Positive | 5 | 1 (20) | 42 | 19 (45) | ||
Treatmentc | 0.6248 | 0.0393 | ||||
No treatment | 4 | 0 (0) | 13 | 8 (62) | ||
Chemotherapy | 1 | 0 (0) | 32 | 14 (44) | ||
Hormone therapy | 21 | 5 (24) | 93 | 31 (33) | ||
Chemotherapy and hormone therapy | 1 | 0 (0) | 9 | 6 (67) | ||